Focus on paroxetine
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
This review of paroxetine is based on Medline and PsycLit searches and a manual search of the available research literature. It aims to cover the pharmacology of this frequently prescribed SSRI antidepressant in terms of its indications, efficacy and adverse effects. Overall, paroxetine is a well-tolerated and safe first-line SSRI antidepressant with anxiolytic qualities. It has been found useful in depression, anxiety and other conditions such as obsessive compulsive disorder and post-traumatic stress disorder. The antidepressant has some advantages over earlier tricyclic medication in terms of a lack of cardiovascular side-effects and relative safety in overdose. Cessation of use, however, is associated with withdrawal or discontinuation symptoms and patients should be counselled as to how these might be avoided. A 3- or 4-week graded withdrawal regimen, perhaps with concomitant fluoxetine to cover serotonergic discontinuation symptoms, may be advisable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kennedy, S. H., Evans, K. R., Krüger, S., Mayberg, H. S., Meyer, J. H., McCann, S., Arifuzzman, A. I., Houle, S., & Vaccarino, F. J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.6.899 · Cited by 710
KELLER, M. B., RYAN, N. D., STROBER, M., KLEIN, R. G., KUTCHER, S. P., BIRMAHER, B., HAGINO, O. R., KOPLEWICZ, H., CARLSON, G. A., CLARKE, G. N., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200107000-00010 · Cited by 641
ROSENBERG, D. R., MacMASTER, F. P., KESHAVAN, M. S., FITZGERALD, K. D., STEWART, C. M., & MOORE, G. J. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200009000-00008 · Cited by 377
Gilbert, A. R., Moore, G. J., Keshavan, M. S., Paulson, L. A. D., Narula, V., Mac Master, F. P., Stewart, C. M., & Rosenberg, D. R. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.449 · Cited by 266
Long‐term evaluation of paroxetine, clomipramine and placebo in panic disorder
Lecrubier, Y., Judge, R., & The Collaborative Paroxetine Panic Study Investigators (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb00389.x · Cited by 139
Hisaoka, K., Nishida, A., Koda, T., Miyata, M., Zensho, H., Morinobu, S., Ohta, M., & Yamawaki, S. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00531.x · Cited by 133 · cited 2×
“More recent theories about the beneficial effects of these antidepressants have focussed on other hypotheses entirely, such as that of Hisaoka et al.39 who have found that that long-term use of SSRIs significantly increases glial cell line-derived neurotrophic factor (GDNF) mRNA expression and GDNF release in a time-…”
BackgroundThe effects of paroxetine and nefazodone on sleep: a placebo controlled trial
Sharpley, A. L., Williamson, D. J., Attenburrow, M. E. J., Pearson, G., Sargent, P., & Cowen, P. J. (1996) · Psychopharmacology · doi:10.1007/bf02246410 · Cited by 122
Adverse events after the abrupt discontinuation of paroxetine
Dominguez, R. A., & Goodnick, P. J. (1995) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1995.tb02896.x · Cited by 57
Medication Withdrawal Symptoms in Obsessive-Compulsive Disorder Patients Treated with Paroxetine
Keuthen, N. J., Cyr, P., Ricciardi, J. A., Minichiello, W. E., Buttolph, M. L., & Jenike, M. A. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199406000-00010 · Cited by 53
Cited by
Himei, A., & Okamura, T. (2006) · CNS Drugs · doi:10.2165/00023210-200620080-00005 · Cited by 56
Murata, Y., Kobayashi, D., Imuta, N., Haraguchi, K., Ieiri, I., Nishimura, R., Koyama, S., & Mine, K. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c8ae80 · Cited by 37
“It has been widely and successfully used in the treatment of major depressive and anxiety disorders.(6) However, clinical studies have reported that the occurrence of discontinuation syndrome is extremely higher in patients treated with paroxetine (ranging 29%Y66%) in comparison with other SSRIs.”
Result
Metadata
- Authors
- Green, B.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2003-01
- Volume
- 19
- Issue
- 1
- Pages
- 13-21
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2123894211
- Cited by
- 187
- References
- 9
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Focus on paroxetine. https://app.cochat.ai/papers/10.1185/030079902125001353
- The paper
- Green, B. (2003). Focus on paroxetine. Current Medical Research and Opinion. https://doi.org/10.1185/030079902125001353
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.